Medlab Clinical Limited
ASX:MDC Stok Raporu
This company listing is no longer active This company may still be operating, however this listing is no longer active. Find out why through their latest events.
See Latest Events Medlab Clinical Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 0/6 Anahtar bilgiler Toplam Hissedar Getirisi -49.8% Gelecekteki Temettü Verimi 0% Temettü Büyümesi n/a Bir sonraki temettü ödeme tarihi n/a Eski temettü tarihi n/a Hisse başına temettü n/a Ödeme oranı n/a
Son temettü ve geri alım güncellemeleri
Tüm güncellemeleri göster
Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded Jan 24
Consensus forecasts updated Jan 13
Price target decreased to AU$18.84 Jan 12
Medlab Announces Interim Readout of Rwe Medcare Study Jan 12
Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis Nov 25
Full year 2022 earnings: EPS and revenues exceed analyst expectations Nov 24
Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update Nov 10
Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update Sep 16
Less than half of directors are independent Sep 02
Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director Aug 31
Full year 2022 earnings: Revenues exceed analyst expectations Aug 31
Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022 Aug 29
Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted Aug 10
Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022 Aug 08
Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program Jun 28
Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program May 31
Less than half of directors are independent Apr 27
Medlab Clinical Ltd Announces Update on NanoCBDTM Apr 12
Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required Feb 08
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now Oct 06
Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth? Oct 05
Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020) Sep 01
Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain Aug 25
Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites Jul 14
CFO, Company Secretary & COO has left the company Apr 07
Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding Mar 21
Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director Mar 19
First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020) Feb 25
What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay Feb 21
Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd Feb 18
Medlab Clinical Limited Receives Positive Depression Trial Prelim Results Feb 11
New 90-day high: AU$0.36 Jan 20
Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm Jan 20
Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years Dec 30
Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway Dec 10
Medlab Clinical Limited Announces NanaBis Observational Study Progression Report Dec 02
New 90-day high: AU$0.26 Nov 30
Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future Nov 22
Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research Nov 11
New 90-day high: AU$0.21 Oct 08
Full year earnings released - AU$0.059 loss per share Aug 29
Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million. Jul 08 Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding Jun 22
Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: MDC şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.
Büyüyen Temettü: MDC şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.
Piyasaya Karşı Temettü Getirisi Medlab Clinical Piyasaya Karşı Temettü Getirisi
MDC temettü verimi piyasa ile karşılaştırıldığında nasıldır? Segment Temettü Verimi Şirket (MDC) n/a Pazarın Alt %25'i (AU) 2.6% Pazarın En İyi %25'i (AU) 6.1% Sektör Ortalaması (Biotechs) 2.1% Analist tahmini (MDC) (3 yıla kadar) 0%
Önemli Temettü: MDC şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.
Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, MDC şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: MDC şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranı nı hesaplamak üzere yeterli veri yok.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: MDC herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.
Güçlü temettü ödeyen şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
